alexa Biological Evidences of Hepatocellular Carcinoma Treatm
ISSN: 2167-7956

Journal of Biomolecular Research & Therapeutics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Biological Evidences of Hepatocellular Carcinoma Treatment with 1,3,4-oxadiazole-2-thiol as Anticancer Agent

Mohamed S Gabry1, Galal H Elgemeie2, Nahed S Basseli3, Samuel T Melek4, Saadia E Hafez3, Omar A Farid5 and Shimaa S Abdelhady3*

1Zoology and Entomology Department, Helwan University, Ain-Helwan, Cairo, Egypt

2Chemistry Department, Helwan University, Ain-Helwan, Cairo, Egypt

3Histology Department, National Organization for Drug Control and Research (NODCAR), 12553, Giza, Egypt

4Parasitology Department, National Organization for Drug Control and Research (NODCAR), 12553, Giza, Egypt

5Physiology Department, National Organization for Drug Control and Research (NODCAR), 12553, Giza, Egypt

*Corresponding Author:
Shimaa S Abdelhady
Histology Department
National Organization for Drug Control and Research (NODCAR)
12553, Giza, Egypt
Tel: +201119691165
E-mail: [email protected]

Received Date: June 07, 2017; Accepted Date: June 12, 2017; Published Date: June 22, 2017

Citation: Gabry MS, Elgemeie GH, Basseli NS, Melek ST, Hafez SE, et al. (2017) Biological Evidences of Hepatocellular Carcinoma Treatment with 1,3,4-oxadiazole-2- thiol as Anticancer Agent. J Biomol Res Ther 6:153. doi: 10.4172/2167-7956.1000153

Copyright: © 2017 Gabry MS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Purpose: In recent years, identification of novel potent, selective, and less toxic anticancer agents remains one of the most pressing health problems. This research aimed to in vivo illustration of 1,3,4-oxadiazole-2-thiol (OXD-T) anticancer activities as a discovery of the treatment of Hepatocellular Carcinoma (HCC) of Albino rats.

Methods: Hepatocellular carcinoma was induced by 3,3’-Diamino benzidine for three months, three times per week. The post treatment of HCC induced rats was carried out with OXD-T therapeutic (300 mg/kg. b.wt.) and half therapeutic doses (150 mg/kg b.wt.) of administration. Biochemical parameters and comet assay were assessed to evaluate the efficiency of OXD-T treatment on the HCC induced animal.

Results: The administration of 1,3,4-oxadiazole-2-thiol (OXD-T) with therapeutic dose and half therapeutic dose to hepatocellular carcinoma (HCC) induced rats affected the biochemical values as biomarkers; prothrombin induced by vitamin K absence-II (PIVKA-II) and lactate dehydrogenase LDH. Also, serum enzymes; AST, ALT, GGT and Albumin. Furthermore, OXD-T affected the DNA fragmentation parameters (tail length, tail moment, % DNA in tail and % DNA in head of comet). OXD-T therapeutic administration revealed highly significant decreases in the biochemical values and DNA fragmentation parameters more than half dose of OXD-T treatment.

Conclusion: OXD-T antimetabolite with different therapeutic doses of administration affected the growth of hepatocellular carcinoma.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords